Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
The use of short-acting beta-2 agonists (SABAs) is more common in elite athletes than in the general population, especially in endurance sports. The World Anti-Doping Code places some restrictions on prescribing inhaled β2-agonists. These drugs are used in respiratory diseases (such as asthma) that...
Saved in:
Main Authors: | Nicolas Vertadier (Author), Wojciech Trzepizur (Author), Sébastien Faure (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncovering the Burden of Rhinitis in Patients Purchasing Nonprescription Short-Acting β-Agonist (SABA) in the Community
by: Sara Alamyar, et al.
Published: (2023) -
First person - Saba Naghipour
Published: (2023) -
The prevalence of overuse injuries in Australian non-elite netballers
by: Bissell L, et al.
Published: (2018) -
Risk factors for overuse injuries in a cohort of elite Swedish track and field athletes
by: Andreas Lundberg Zachrisson, et al.
Published: (2021) -
Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
by: Burkes RM, et al.
Published: (2020)